Alzinova: Positive final results from phase Ib study - Redeye

Redeye leaves a comment following Alzinova’s announcement of final study results from the phase Ib study with its vaccine candidate ALZ-101. We are encouraged to learn that the final results reinstate the positive data from the previous topline results, suggesting that ALZ-101 is well-tolerated and safe, elicits a high immune response in patients and shows indications of efficacy on cognitive and functional parameters.

Länk till analysen i sin helhet: https://www.redeye.se/research/1091415/alzinova-positive-final-results-from-phase-ib-study?utm_source=finwire&utm_medium=RSS